Last reviewed · How we verify
Placebo to Mepolizumab
Placebo to Mepolizumab is a IL-5 inhibitor Biologic drug developed by AstraZeneca. It is currently in Phase 3 development for Severe asthma with an eosinophilic phenotype, Eosinophilic granulomatosis with polyangiitis (EGPA).
Mepolizumab is an interleukin-5 (IL-5) inhibitor that blocks the action of IL-5, a cytokine involved in the production and survival of eosinophils.
Mepolizumab is an interleukin-5 (IL-5) inhibitor that blocks the action of IL-5, a cytokine involved in the production and survival of eosinophils. Used for Severe asthma with an eosinophilic phenotype, Eosinophilic granulomatosis with polyangiitis (EGPA).
At a glance
| Generic name | Placebo to Mepolizumab |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | IL-5 inhibitor |
| Target | IL-5 |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
IL-5 is a key cytokine in the development and activation of eosinophils, which are a type of white blood cell involved in allergic reactions and asthma. By inhibiting IL-5, mepolizumab reduces the production and survival of eosinophils, which can help to reduce inflammation and symptoms in patients with asthma and hypereosinophilic syndrome.
Approved indications
- Severe asthma with an eosinophilic phenotype
- Eosinophilic granulomatosis with polyangiitis (EGPA)
Common side effects
- Headache
- Injection site reaction
- Nausea
- Diarrhea
- Muscle pain
Key clinical trials
- Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab. (PHASE3)
- Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease (PHASE2)
- A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA） (PHASE2, PHASE3)
- Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) (PHASE3)
- Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge) (PHASE3)
- A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype (PHASE3)
- Biologics in Chronic Rhinosinusitis With Nasal Polyposis (PHASE4)
- Mepolizumab for the Treatment of Chronic Spontaneous Urticaria (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to Mepolizumab CI brief — competitive landscape report
- Placebo to Mepolizumab updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Placebo to Mepolizumab
What is Placebo to Mepolizumab?
How does Placebo to Mepolizumab work?
What is Placebo to Mepolizumab used for?
Who makes Placebo to Mepolizumab?
What drug class is Placebo to Mepolizumab in?
What development phase is Placebo to Mepolizumab in?
What are the side effects of Placebo to Mepolizumab?
What does Placebo to Mepolizumab target?
Related
- Drug class: All IL-5 inhibitor drugs
- Target: All drugs targeting IL-5
- Manufacturer: AstraZeneca — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Severe asthma with an eosinophilic phenotype
- Indication: Drugs for Eosinophilic granulomatosis with polyangiitis (EGPA)